Pepscan announces research collaboration with Fusion Pharmaceuticals to discover and develop peptide-based radiopharmaceuticals

Pepscan, the all-in-one peptide service provider with proprietary peptide constraining technologies, today announced a strategic research collaboration with Fusion Pharmaceuticals to discover novel, peptide-based radiopharmaceuticals for the treatment of various solid tumors. Pepscan’s unique CLIPS™ phage display platform will screen billions of peptides to discover highly constrained de novo peptides with enhanced affinities, selectivities, and proteolytic stabilities.

“We are pleased to partner with Pepscan, a global leader in peptide discovery with a platform that will enable us to create novel, peptide-based targeted alpha therapies (TATs), further augmenting our pipeline of radiopharmaceuticals,” said Fusion Chief Executive Officer John Valliant.

Read further